Nymox secures Italian deal for Alzheimer's test:
This article was originally published in Clinica
Nymox Pharmaceutical, of Maywood, New Jersey, has entered into a distribution agreement with Padua-based Italian medical diagnostics company Alifax, to market and sell Nymox's AlzheimAlert product in Italy. Nymox's urine test, an aid in the diagnosis of Alzheimer's disease, is available through the company's CLIA-certified clinical reference laboratory in the US, although a PMA application was rejected by the FDA last year and a second application has been lodged (see Clinica 1136, p 18). A recent report by the World Health Organization for the European Union has identified Alzheimer's disease as a major healthcare priority for Europe. Worldwide estimates of the current number of people with the condition range from 15 to 20 million.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.